COMMUNIQUÉS West-GlobeNewswire

-
Microbix Launches QUANTDx™ Characterized Reference Materials
29/07/2025 -
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
29/07/2025 -
Novo Nordisk lowers sales and operating profit outlook for 2025
29/07/2025 -
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
29/07/2025 -
Quipt Home Medical Corp. to Announce Fiscal Third Quarter 2025 Financial Results on August 11, 2025
29/07/2025 -
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
29/07/2025 -
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
29/07/2025 -
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
29/07/2025 -
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
29/07/2025 -
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
29/07/2025 -
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
29/07/2025 -
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
29/07/2025 -
Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies
29/07/2025 -
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
29/07/2025 -
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
29/07/2025 -
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
29/07/2025 -
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
29/07/2025 -
Exagen Inc. Reports Strong Q2 2025 Results
29/07/2025 -
Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration
29/07/2025
Pages